Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

New York, New York-- (Newsfile Corp. - February 19, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) ...

These latest developments come just a few weeks after DeepSeek's release of a lower-cost AI model rattled markets, as it sparked concerns about the level of spending by major US tech companies in this ...

GSK said its five-in-one meningococcal vaccine Penmenvy was approved by the U.S. Food and Drug Administration. The British pharmaceutical company on Monday said the vaccine was authorized for use in ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand ...

When the company faced the possibility of owing Medicaid reimbursements for those excessive price hikes, it stopped making Flovent, the lawsuit says, "GSK put corporate greed ahead of the health ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

2025 Core Operating Profit and EPS Guidance: Expected to increase between 6% and 8%. GSK PLC (NYSE:GSK) reported an 8% increase in sales for 2024, reaching over GBP31 billion, driven by strong ...